SIDMAP Collaboration Leads to Discovery of Novel Biomarker for Early Detection the Metabolic Syndrome

LOS ANGELES--(BUSINESS WIRE)--SiDMAP, LLC, a provider of metabolic profiling and biomarker development services to the pharmaceutical and biotechnology industries, announced today the discovery of an early metabolic marker for detecting the emergence of metabolic syndrome in patients taking certain anti-psychotic medications, and potentially, in the general population. The emergence of the metabolic syndrome previously linked to the long term use of certain anti-psychotic medications may now be determined long before any current means of detection, using a new biomarker discovered using SiDMAP’s proprietary metabolic profiling platform.